Olfactory neuron-specific expression of A30P alpha-synuclein exacerbates dopamine deficiency and hyperactivity in a novel conditional model of early Parkinson's disease stages

Neurobiology of Disease

Volumn 44, Issue 2, 2011, Pages 192-204

  Nuber, Silke ^a   Petrasch Parwez, Elisabeth ^b   Arias Carrión, Oscar ^c   Koch, Leanie ^c   Kohl, Zacharias ^d   Schneider, Jacqueline ^d   Calaminus, Carsten ^a   Dermietzel, Rolf ^b   Samarina, Anna ^a   Boy, Jana ^a   Nguyen, Huu P ^a   Teismann, Peter ^e   Velavan, Thirumalaisamy Palanichamy ^a   Kahle, Philipp J ^f   von Hörsten, Stephan ^g   Fendt, Markus ^a,h   Krüger, Rejko ^f   Riess, Olaf ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; BRAIN STEM; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; GENE MUTATION; GENETIC CODE; HYPERACTIVITY; IMMUNOHISTOCHEMISTRY; MESENCEPHALON; MOTOR DYSFUNCTION; MOUSE; NEUROPSYCHIATRY; NEUROTRANSMITTER RELEASE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OLFACTORY BULB; OLFACTORY SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; SYMPTOMATOLOGY; TRANSGENIC MOUSE;

ALPHA-SYNUCLEIN; AMINO ACID SUBSTITUTION; ANIMALS; CRICETINAE; DISEASE MODELS, ANIMAL; DOPAMINE; FEMALE; HUMANS; HYPERKINESIS; MALE; MICE; MICE, TRANSGENIC; MUTATION; NEURONS; OLFACTORY BULB; PARKINSONIAN DISORDERS;

EID: 80052287774     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.06.017     Document Type: Article

References (91)

1. Abeliovich A., Schmitz Y., Fariñas I., Choi-Lundberg D., Ho W.H., Castillo P.E., Shinsky N., Verdugo J.M., Armanini M., Ryan A., Hynes M., Phillips H., Sulzer D., Rosenthal A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25:239-252.
2. Albin R.L., Koeppe R.A., Bohnen N.I., Wernette K., Kilbourn M.A., Frey K.A. Spared caudal brainstem SERT binding in early Parkinson's disease. J. Cereb. Blood Flow Metab. 2008, 28:441-444.
3. Andres K.H. The fine structure of the olfactory bulb in rats with special reference to synaptic connections. Zellforsch. Mikrosk. Anat. 1965, 65:530-561.
4. Apfelbach R., Blanchard C.D., Blanchard R.J., Hayes R.A., McGregor I.S. The effects of predator odors in mammalian prey species: a review of field and laboratory studies. Neurosci. Biobehav. Rev. 2005, 29:1123-1144.
5. Baba T., Takeda A., Kikuchi A., Nishio Y., Hosokai Y., Hirayama K., Hasegawa T., Sugeno N., Suzuki K., Mori E., Takahashi S., Fukuda H., Itoyama Y. Association of olfactory dysfunction and brain. Metabolism in Parkinson's disease. Mov. Disord. 2011, 26:621-628.
6. Beach T.G., White C.L., Hladik C.L., Sabbagh M.N., Connor D.J., Shill H.A., Sue L.I., Sasse J., Bachalakuri J., Henry-Watson J., Akiyama H., Adler C.H. Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol. 2009, Feb(117):169-174. Arizona Parkinson's Disease Consortium.
7. Berkowicz D.A., Trombley P.Q. Dopaminergic modulation at the olfactory nerve synapse. Brain Res. 2000, 855:90-99.
8. Bertoncini C.W., Fernandez C.O., Griesinger C., Jovin T.M., Zweckstetter M. Familial mutants of alpha-synuclein with increased neurotoxicity have a destabilized conformation. J. Biol. Chem. 2005, 280:30649-30652.
9. Braak H., Del Tredici K., Rüb U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
10. Bohnen N.I., Gedela S., Herath P., Constantine G.M., Moore R.Y. Selective hyposmia in Parkinson disease: association with hippocampal dopamine activity. Neurosci. Lett. 2008, 447:12-16.
11. Boy J., Leergaard T.B., Schmidt T., Odeh F., Bichelmeier U., Nuber S., Holzmann C., Wree A., Prusiner S.B., Bujard H., Riess O., Bjaalie J.G. Expression mapping of tetracycline-responsive prion protein promoter: digital atlasing for generating cell-specific disease models. Neuroimage 2006, 33:449-462.
12. Buron G., Hacquemand R., Pourie G., Lucarz A., Jacquot L., Brand G. Comparative behavioral effects between synthetic 2,4,5-trimethylthiazoline (TMT) and the odor of natural fox (Vulpes vulpes) feces in mice. Behav. Neurosci. 2007, 121:1063-1072.
13. Brunjes P.C., Smith-Crafts L.K., McCarty R. Unilateral odor deprivation: effects on the development of olfactory bulb catecholamines and behavior. Brain Res. 1985, 54:1-6.
14. Chandra S., Gallardo G., Fernández-Chacón R., Schlüter O.M., Südhof T.C. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005, 123:383-396.
15. Choi W., Zibaee S., Jakes R., Serpell L.C., Davletov B., Crowther R.A. Goedert M (2004) Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett. 2004, 576(3):363-368. Oct 22.
16. Chu Y., Kordower J.H. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease?. Neurobiol. Dis. 2007, 25:134-149.
17. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295.
18. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Harper J.D., Williamson R.E., Lansbury P.T. Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Ann. N. Y. Acad. Sci. 2000, 920:42-45.
19. Daniel S.E., Hawkes C.H. Preliminary diagnosis of Parkinson's disease by olfactory bulb pathology. Lancet 1992, 340:186.
20. Davila N.G., Blakemore L.J., Trombley P.Q. Dopamine modulates synaptic transmission between rat olfactory bulb neurons in culture. J. Neurophysiol. 2003, 90:395-404.
21. Del Tredici K., Rüb U., De Vos R.A., Bohl J.R., Braak H. Where does parkinson disease pathology begin in the brain?. J. Neuropathol. Exp. Neurol. 2002, 61:413-246.
22. Doty R.L., Stern M.B., Pfeiffer C., Gollomp S.M., Hurtig H.I. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1992, 55:138-142.
23. Ennis M., Zhou F.M., Ciombor K.J., Aroniadou-Anderjaska V., Hayar A., Borrelli E., Zimmer L.A., Margolis F., Shipley M.T. Dopamine D2 receptor-mediated presynaptic inhibition of olfactory nerve terminals. J. Neurophysiol. 2001, 86:2986-2997.
24. Esposito A., Dohm C.P., Kermer P., Bähr M., Wouters F.S. alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton. Neurobiol. Dis. 2007, 26:521-531.
25. Fendt M., Endres T., Lowry C.A., Apfelbach R., McGregor I.S. TMT-induced autonomic and behavioral changes and the neural basis of its processing. Neurosci. Biobehav. Rev. 2005, 29:1145-1156.
26. Fendt M., Endres T. 2,3,5-Trimethyl-3-thiazoline (TMT), a component of fox odor - just repugnant or really fear-inducing?. Neurosci. Biobehav. Rev. 2008, 32:1259-1266.
27. Freeman W. Olfactory system: odorant detection and classification. Building Blocks for Intelligent Systems: Brain Components as Elements of Intelligent Function, vol. III, part 2 1999, Academic Press, New York. D. Amit, G. Parisi (Eds.).
28. Freichel C., Neumann M., Ballard T., Müller V., Woolley M., Ozmen L., Borroni E., Kretzschmar H.A., Haass C., Spooren W., Kahle P.J. Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. Neurobiol. Aging 2007, 28:1421-1435.
29. Gomez-Isla T., Irizarry M.C., Mariash A., Cheung B., Soto O., Schrump S., Sondel J., Kotilinek L., Day J., Schwarzschild M.A., Cha J.H., Newell K., Miller D.W., Uéda K., Young A.B., Hyman B.T., Ashe K.H. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol. Aging 2003, 24:245-258.
30. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl Acad. Sci. USA 1992, 89:5547-5551.
31. Gossen M., Freundlieb S., Bender G., Muller G., Hillen W., Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995, 268:1766-1769.
32. Graham D.R., Sidhu A. Mice expressing the A53T mutant form of human alpha-synuclein exhibit hyperactivity and reduced anxiety-like behavior. J. Neurosci. Res. 2010, 88:1777-1783.
33. Guthrie K.M., Wilson D.A., Leon M. Early unilateral deprivation modifies olfactory bulb function. J. Neurosci. 1990, 10:3402-3412.
34. Hashimoto M., Masliah E. Alpha-synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol. 1999, 9:707-720.
35. Hoogland P.V., Huisman E. Tyrosine hydroxylase immunoreactive structures in the aged human olfactory bulb and olfactory peduncle. J. Chem. Neuroanat. 1999, 17:153-161.
36. Hsia A.Y., Vincent J.D., Lledo P.M. Dopamine depresses synaptic inputs into the olfactory bulb. J. Neurophysiol. 1999, 82:1082-1085.
37. Hubbard P.S., Esiri M.M., Reading M., McShane R., Nagy Z. Alpha-synuclein pathology in the olfactory pathways of dementia patients. J. Anat. 2007, 211:117-124.
38. Huisman E., Uylings H.B., Hoogland P.V. A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease. Mov. Disord. 2004, 19:687-692.
39. Huisman E., Uylings H.B., Hoogland P.V. Gender-related changes in increase of dopaminergic neurons in the olfactory bulb of Parkinson's disease patients. Mov. Disord. 2008, 23:1407-1413.
40. Jensen P.H., Nielsen M.S., Jakes R., Dotti C.G., Goedert M. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 1998, 273:26292-26294.
41. Jo E., Fuller N., Rand R.P., St George-Hyslop P., Fraser P.E. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. J. Mol. Biol. 2002, 315:799-807.
42. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Schindzielorz A., Okochi M., Leimer U., van Der Putten H., Probst A., Kremmer E., Kretzschmar H.A., Haass C. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 2000, 20:6365-6373.
43. Katzenschlager R., Lees A.J. Olfaction and Parkinson's syndromes: its role in differential diagnosis. Curr. Opin. Neurol. 2004, 17:417-423.
44. Kertelge L., Brüggemann N., Schmidt A., Tadic V., Wisse C., Dankert S., Drude L., van der Vegt J., Siebner H., Pawlack H., Pramstaller P.P., Behrens M.I., Ramirez A., Reichel D., Buhmann C., Hagenah J., Klein C., Lohmann K., Kasten M. Impaired sense of smell and color discrimination in monogenic and idiopathic Parkinson's disease. Mov. Disord. 2010, 25:2665-2669.
45. Krüger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
46. Krüger R., Kuhn W., Leenders K.L., Sprengelmeyer R., Müller T., Woitalla D., Portman A.T., Maguire R.P., Veenma L., Schröder U., Schöls L., Epplen J.T., Riess O., Przuntek H. Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology 2001, 56:1355-1362.
47. Kurz A., Double K.L., Lastres-Becker I., Tozzi A., Tantucci M., Bockhart V., Bonin M., García-Arencibia M., Nuber S., Schlaudraff F., Liss B., Fernández-Ruiz J., Gerlach M., Wüllner U., Lüddens H., Calabresi P., Auburger G., Gispert S. A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. PLoS One 2010, 5:e11464.
48. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., Dawson T.M., Copeland N.G., Jenkins N.A., Price D.L. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53→Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl Acad. Sci. USA 2002, 99:8968-8973.
49. Li J., Uversky V.N., Fink A.L. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochem. 2001, 40:11604-11613.
50. Malisch J.L., Breuner C.W., Kolb E.M., Wada H., Hannon R.M., Chappell M.A., Middleton K.M., Garland T. Behavioral despair and home-cage activity in mice with chronically elevated baseline corticosterone concentrations. Behav. Genet. 2009, 39:192-201.
51. Malkesman O., Scattoni M.L., Paredes D., Tragon T., Pearson B., Shaltiel G., Chen G., Crawley J.N., Manji H.K. The female urine sniffing test: a novel approach for assessing reward-seeking behavior in rodents. Biol. Psychiatry 2010, 67:864-871.
52. Markopoulou K., Larsen K.W., Wszolek E.K., Denson M.A., Lang A.E., Pfeiffer R.F., Wszolek Z.K. Olfactory dysfunction in familial parkinsonism. Neurology 1997, 49:1262-1267.
53. Marxreiter F., Nuber S., Kandasamy M., Klucken J., Aigner R., Burgmayer R., Couillard-Despres S., Riess O., Winkler J., Winner B. Changes in adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of alpha-synuclein. Eur. J. Neurosci. 2009, 29:879-890.
54. Mesholam R.I., Moberg P.J., Mahr R.N., Doty R.L. Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's diseases. Arch. Neurol. 1998, 55:84-90.
55. Mori K., Nagao H., Yoshihara Y. The olfactory bulb: coding and processing of odor molecule information. Science 1999, 286:711-715.
56. Morrow B.A., Redmond A.J., Roth R.H., Elsworth J.D. The predator odor, TMT, displays a unique, stress-like pattern of dopaminergic and endocrinological activation in the rat. Brain Res. 2000, 864:146-151.
57. Morrow B.A., Roth R.H., Elsworth J.D. TMT, a predator odor, elevates mesoprefrontal dopamine metabolic activity and disrupts short-term working memory in the rat. Brain Res. Bull. 2000, 52:519-523.
58. Müller T., Fuchs G., Hahne M., Klein W., Schwarz M. Diagnostic aspects of early Parkinson's disease. J. Neurol. 2006, Suppl. 4:IV29-IV31.
59. Mundiñano I.C., Caballero M.C., Ordóñez C., Hernandez M., Dicaudo C., Marcilla I., Erro M.E., Tuñon M.T., Luquin M.R. Increased dopaminergic cells and protein aggregates in the olfactory bulb of patients with neurodegenerative disorders. Acta Neuropathol. 2011.
60. Nemani V.M., Lu W., Berge V., Nakamura K., Onoa B., Lee M.K., Chaudhry F.A., Nicoll R.A., Edwards R.H. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010, 65:66-79.
61. Neumann M., Kahle P.J., Giasson B.I., Ozmen L., Borroni E., Spooren W., Müller V., Odoy S., Fujiwara H., Hasegawa M., Iwatsubo T., Trojanowski J.Q., Kretzschmar H.A., Haass C. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Investig. 2002, 110:1429-1439.
62. Nuber S., Petrasch-Parwez E., Winner B., Winkler J., von Hörsten S., Schmidt T., Boy J., Kuhn M., Nguyen H.P., Teismann P., Schulz J.B., Neumann M., Pichler B.J., Reischl G., Holzmann C., Schmitt I., Bornemann A., Kuhn W., Zimmermann F., Servadio A., Riess O. Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J. Neurosci. 2008, 28:2471-2484.
63. Paxinos G., Franklin K.B. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, San Diego, CA. 2nd ed.
64. Perez R.G., Waymire J.C., Lin E., Liu J.J., Guo F., Zigmond M.J. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 2002, 22:3090-3099.
65. Petrasch-Parwez E., Nguyen H.P., Löbbecke-Schumacher, Habbes H.W., Wieczorek S., Riess O., Andres K.H., Dermietzel R., v.Hörsten S. Cellular and subcellular localization of Huntingtin aggregates (corrected) in the brain of a rat transgenic for Huntington disease. J. Comp. Neurol. 2007, 501:716-730.
66. Pignatelli A., Ackman J.B., Vigetti D., Beltrami A.P., Zucchini S., Belluzzi O. A potential reservoir of immature dopaminergic replacement neurons in the adult mammalian olfactory bulb. Pflügers Arch. 2009, 457:899-915.
67. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
68. Ponsen M.M., Stoffers D., Booij J., van Eck-Smit B.L., Wolters E.Ch., Berendse H.W. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann. Neurol. 2004, 56:173-181.
69. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 1977, 229:327-336.
70. Seidel K., Schöls L., Nuber S., Petrasch-Parwez E., Gierga K., Wszolek Z., Dickson D., Gai W.P., Bornemann A., Riess O., Rami A., Den Dunnen W.F., Deller T., Rüb U., Krüger R. First appraisal of brain pathology owing to A30P mutant alpha-synuclein. Ann. Neurol. 2010, 67:684-689.
71. Sengoku R., Saito Y., Ikemura M., Hatsuta H., Sakiyama Y., Kanemaru K., Arai T., Sawabe M., Tanaka N., Mochizuki H., Inoue K., Murayama S. Incidence and extent of Lewy body-related alpha-synucleinopathy in aging human olfactory bulb. J. Neuropathol. Exp. Neurol. 2008, 267:1072-1083.
72. Silveira-Moriyama L., Holton J.L., Kingsbury A., Ayling H., Petrie A., Sterlacci W., Poewe W., Maier H., Lees A.J., Revesz T. Regional differences in the severity of Lewy body pathology across the olfactory cortex. Neurosci. Lett. 2009, 453:77-80.
73. Song C., Leonard B.E. The olfactory bulbectomised rat as a model of depression. Neurosci. Biobehav. Rev. 2005, 29:627-647.
74. Tanda K., Nishi A., Matsuo N., Nakanishi K., Yamasaki N., Sugimoto T., Toyama K., Takao K., Miyakawa T. Abnormal social behavior, hyperactivity, impaired remote spatial memory, and increased D1-mediated dopaminergic signaling in neuronal nitric oxide synthase knockout mice. Mol. Brain 2009, 2:19.
75. Tremblay P., Meiner Z., Galou M., Heinrich C., Petromilli C., Lisse T., Cayetano J., Torchia M., Mobley W., Bujard H., DeArmond S.J., Prusiner S.B. Doxycycline control of prion protein transgene expression modulates prion disease in mice. Proc. Natl Acad. Sci. USA 1998, 95:12580-12585.
76. Ubeda-Bañon I., Novejarque A., Mohedano-Moriano A., Pro-Sistiaga P., de la Rosa-Prieto C., Insausti R., Martinez-Garcia F., Lanuza E., Martinez-Marcos A. Projections from the posterolateral olfactory amygdala to the ventral striatum: neural basis for reinforcing properties of chemical stimuli. BMC Neurosci. 2007, 8:103.
77. Ubeda-Bañon I., Saiz-Sanchez D., de la Rosa-Prieto C., Argandoña-Palacios L., Garcia-Muñozguren S., Martinez-Marcos A. alpha-Synucleinopathy in the human olfactory system in Parkinson's disease: involvement of calcium-binding protein- and substance P-positive cells. Acta Neuropathol. 2010, 119:723-735.
78. Unger E.L., Eve D.J., Perez X.A., Reichenbach D.K., Xu Y., Lee M.K., Andrews A.M. Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice. Neurobiol. Dis. 2006, 21:431-443.
79. Viggiano D. The hyperactive syndrome: metanalysis of genetic alterations, pharmacological treatments and brain lesions which increase locomotor activity. Behav. Brain Res. 2008, 194:1-14.
80. Wakamatsu M., Ishii A., Iwata S., Sakagami J., Ukai Y., Ono M., Kanbe D., Muramatsu S., Kobayashi K., Iwatsubo T., Yoshimoto M. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. Neurobiol. Aging 2008, 29:574-585.
81. West M.J. New stereological methods for counting neurons. Neurobiol. Aging 1993, 14:275-285.
82. Wahle P., Sanides-Kohlrausch C., Meyer G., Lubke J. Substance P- and opioid immunoreactive structures in olfactory centers of the cat: adult pattern and postnatal development. Comp. Neurol. 1990, 302:349-369.
83. Wersinger C., Rusnak M., Sidhu A. Modulation of the trafficking of the human serotonin transporter by human alpha-synuclein. Eur. J. Neurosci. 2006, 24:55-64.
84. Wersinger C., Sidhu A. Disruption of the interaction of alpha-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter. Biochemistry 2005, 44:13612-13624.
85. Wilson D.A., Wood J.G. Functional consequences of unilateral olfactory deprivation: time-course and age sensitivity. Neuroscience 1992, 49:183-192.
86. Wilson D.A., Sullivan R.M. The D2 antagonist spiperone mimics the effects of olfactory deprivation on mitral/tufted cell odor response patterns. J. Neurosci. 1995, 15:5574-5581.
87. Wilson D.A., Stevenson R.J. Olfactory perceptual learning: the critical role of memory in odor discrimination. Neurosci. Biobehav. Rev. 2003, 27:307-328.
88. Winner B., Lie D.C., Rockenstein E., Aigner R., Aigner L., Masliah E., Kuhn H.G., Winkler J. Human wild-type alpha-synuclein impairs neurogenesis. J. Neuropathol. Exp. Neurol. 2004, 63:1155-1166.
89. Yavich L., Tanila H., Vepsäläinen S., Jäkälä P. Role of alpha-synuclein in presynaptic dopamine recruitment. J. Neurosci. 2004, 24:11165-11170.
90. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Gomez Tortosa E., del Ser T., Munoz D.G., de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.
91. Zueger M., Urani A., Chourbaji S., Zacher C., Roche M., Harkin A., Gass P. Olfactory bulbectomy in mice induces alterations in exploratory behavior. Neurosci. Lett. 2005, 374:142-146.